Avtor/Urednik		Škrbinc, Breda
Naslov		Embolizacija kot del zdravljenja svetloceličnega karcinoma ledvic
Tip		članek
Vir		In: Kozak M, Blinc A, Šabovič M, editors. Žilne bolezni in rak; 2006 apr; Šmarješke toplice. Ljubljana: Združenje za žilne bolezni,
Leto izdaje		2006
Obseg		str. 57-64
Jezik		slo
Abstrakt		Patients with renal cell carcinoma account for 2%-3% of all cancer patients. Localized disease can be successfully treated with radical nephrectomy while for decades there has been no successful treatment for patients with metastatic disease. Objective response rate with standard imunomodulatory treatment with interferon-alfa, (IF-alfa) and interleukin-2 (IL-2) is low and usually short-lived. Better understanding of cancer-cell biology has established targeted therapy against metastatic renal cell carcinoma. Target drugs act against specific molecular targets in cancer cells which are of crucial importance for cancer-cell survival and their proliferation. The role of transarterial embolisation (TAE) in the treatment of localized disease has not yet been established while the method is of clear importance in treating hemorrhagic complications of metastatic renal cell carcinoma as well as in diminishing hemorrhagic complications during surgical resection of skeletal metastases.
Deskriptorji		KIDNEY NEOPLASMS CARCINOMA, RENAL CELL EMBOLIZATION, THERAPEUTIC